BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 2110815)

  • 21. Mechanism of oncogenicity for bioreductive drugs.
    Hei TK; Piao CQ; He ZY; Hall EJ
    Int J Radiat Oncol Biol Phys; 1992; 22(4):747-50. PubMed ID: 1544847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Variation of the radiosensitizing efficiency of RSU-1069 with pre-irradiation contact times: a rapid mix study.
    Austen KR; Jenner TJ; O'Neill P; Fielden EM
    Int J Radiat Biol Relat Stud Phys Chem Med; 1987 Aug; 52(2):281-8. PubMed ID: 3497125
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanisms of hypoxic and aerobic cytotoxicity of mitomycin C in Chinese hamster V79 cells.
    Krishna MC; DeGraff W; Tamura S; Gonzalez FJ; Samuni A; Russo A; Mitchell JB
    Cancer Res; 1991 Dec; 51(24):6622-8. PubMed ID: 1660344
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual-function radiation sensitizers and bioreductive drugs: factors affecting cellular uptake and sensitizing efficiency in analogues of RSU 1069.
    Walling J; Stratford IJ; Adams GE; Stephens MA
    Int J Radiat Biol Relat Stud Phys Chem Med; 1988 Apr; 53(4):641-9. PubMed ID: 3258298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oxygen and exposure kinetics as factors influencing the cytotoxicity of porfiromycin, a mitomycin C analogue, in Chinese hamster ovary cells.
    Marshall RS; Rauth AM
    Cancer Res; 1988 Oct; 48(20):5655-9. PubMed ID: 3167822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiosensitizing and cytotoxic effects of nitroimidazoles in CHO cells expressing elevated levels of glutathione-S-transferase.
    Stratford IJ; Hickson ID; Robson CN; Stephens M
    Int J Radiat Oncol Biol Phys; 1989 May; 16(5):1307-10. PubMed ID: 2523884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line.
    Saunders MP; Patterson AV; Chinje EC; Harris AL; Stratford IJ
    Br J Cancer; 2000 Feb; 82(3):651-6. PubMed ID: 10682679
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Studies of the in vivo and in vitro cytotoxicity of the drug RSU-1069.
    Hill RP; Gulyas S; Whitmore GF
    Br J Cancer; 1986 Jun; 53(6):743-51. PubMed ID: 3755053
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of pH on the aerobic and hypoxic cytotoxicity of SR4233 in HT-29 cells.
    Skarsgard LD; Skwarchuk MW; Vinczan A; Chaplin DJ
    Br J Cancer; 1993 Oct; 68(4):681-3. PubMed ID: 8398693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DNA damaging effects and voltammetric studies on the hypoxic cell toxin 3-amino-1,2,4-benzotriazine-1,4-dioxide, SR4233, as a function of pH.
    Tocher JH; Virk NS; Edwards DI
    Biochem Pharmacol; 1990 Sep; 40(6):1405-10. PubMed ID: 2144963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The differential cytotoxicity of RSU 1069: cell survival studies indicating interaction with DNA as a possible mode of action.
    Stratford IJ; Walling JM; Silver AR
    Br J Cancer; 1986 Mar; 53(3):339-44. PubMed ID: 3754453
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bioreductive therapies: an overview of drugs and their mechanisms of action.
    Rauth AM; Melo T; Misra V
    Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):755-62. PubMed ID: 9845091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The repair of DNA damage induced in V79 mammalian cells by the nitroimidazole-aziridine, RSU-1069. Implications for radiosensitization.
    Jenner TJ; O'Neill P; Crump PW; Fielden EM; Sapora O; Santodonato L
    Biochem Pharmacol; 1991 Oct; 42(9):1705-10. PubMed ID: 1930296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of radiation and tirapazamine (SR-4233) on three melanoma cell lines.
    Zhang M; Stevens G
    Melanoma Res; 1998 Dec; 8(6):510-5. PubMed ID: 9918413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deficient activation by a human cell strain leads to mitomycin resistance under aerobic but not hypoxic conditions.
    Marshall RS; Paterson MC; Rauth AM
    Br J Cancer; 1989 Mar; 59(3):341-6. PubMed ID: 2467684
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bioreductive drugs: from concept to clinic.
    McKeown SR; Cowen RL; Williams KJ
    Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):427-42. PubMed ID: 17482438
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The influence of hypoxia on the cytotoxicity of concomitant KW-2149 and ionizing irradiation in Chinese hamster fibroblasts.
    Egelmeers A; Dirix LY; Lyczek J; De Bruijn EA; Van Oosterom AT; Scalliet P
    Anticancer Drugs; 1996 Jul; 7(5):586-90. PubMed ID: 8862727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypoxic cells as specific drug targets for chemotherapy.
    Kennedy KA
    Anticancer Drug Des; 1987 Oct; 2(2):181-94. PubMed ID: 3130070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [In vitro oxygen-dependent survival of 2 human cell lines after radiation combined with tirapazamine (SR-4233) and cisplatin].
    Lartigau E; Stern S; Guichard M
    Cancer Radiother; 2000; 4(3):217-22. PubMed ID: 10897765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bioreduction of RSU 1069 and mitomycin C after dearterialization.
    Wang LQ; Persson BG; Bengmark S
    Eur J Surg Oncol; 1993 Oct; 19(5):455-62. PubMed ID: 8405482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.